Stryker’s $4.9 B Inari Medical Buy as Medtech Volumes Grow Mid-High Singles
Medtech volumes climbed mid-to-high-single digits with pricing stable, while sector valuation multiples compressed due to investor focus on AI leaders and Middle East uncertainties. Stryker completed its $4.9 billion acquisition of Inari Medical in 2025, expanding its clot-removal portfolio amid sustained M&A activity.
1. Industry Volume and Pricing
Medtech industry volumes rose mid-to-high-single digits year-over-year in 2025, with pricing remaining stable despite geopolitical headwinds. Rising procedural demand and consistent device utilization drove the underlying fundamentals.
2. Valuation Multiple Compression
Medtech sector valuation multiples compressed as investors rotated capital into AI-focused companies and reacted to Middle East supply chain uncertainties. Higher-growth names saw their premiums narrow closer to lower-growth peers.
3. Stryker’s Inari Acquisition
Stryker closed a $4.9 billion acquisition of Inari Medical in 2025, bolstering its thrombectomy and clot-removal portfolio. This transaction aligns with Stryker’s strategy to diversify its cardiovascular and neurovascular offerings.
4. Future Outlook
Analysts expect a potential re-rating of medtech stocks as AI integration advances and Middle East tensions ease, potentially restoring sector premium valuations. Stryker’s expanded product pipeline and stable pricing position it well for this shift.